Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics, Inc.’s Chief Legal Officer and General Counsel Elizabeth E. Reed exercised employee stock options and sold shares of common stock in a series of transactions. She exercised options to acquire 37,500 shares at exercise prices of $19.08, $17.96, and $15.46 per share and also received 14,000 shares as a grant or award.
Ms. Reed then sold a total of 51,500 shares of common stock in open-market and related transactions at weighted average prices around $41–$43 per share, leaving her with 105,211 shares owned directly after the transactions. Footnotes state that certain sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025 and that part of the sales were mandatory “sell to cover” trades to satisfy tax withholding obligations.
The 14,000-share award reflects performance restricted stock units granted on January 31, 2025 that vested on April 13, 2026 after the U.S. Food and Drug Administration approved FILSPARI (sparsentan) in FSGS.
Travere Therapeutics’ chief financial officer, Christopher R. Cline, reported a mix of equity compensation and share sales in Travere Therapeutics, Inc. common stock. He received 14,000 shares on April 13, 2026 as a grant tied to performance restricted stock units that vested after the U.S. Food and Drug Administration approved FILSPARI (sparsentan) for FSGS.
Between April 13 and 15, 2026, he sold a total of 8,327 shares in open-market transactions at prices ranging from about $28.85 to $42.61. Footnotes explain that part of these sales were mandated “sell to cover” transactions to satisfy tax withholding on vested restricted and performance stock units, and others were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 28, 2025. After these transactions, he directly holds 116,899 shares of Travere common stock.
Travere Therapeutics’ chief medical officer Jula Inrig reported a mix of equity award vesting and routine share sales. On April 13, 2026, 14,000 shares of common stock were acquired at no cost upon the vesting of performance restricted stock units tied to FDA approval of FILSPARI (sparsentan) in FSGS.
On April 14, 2026, Inrig sold 7,215 shares of common stock at an average price of $41.9288 per share in open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on May 28, 2025. On April 15, 2026, a further 1,018 shares were sold at $42.61 per share to cover tax withholding obligations related to the PSU settlement, as required by the company’s equity incentive plans. Following these transactions, Inrig held 111,473 shares of Travere Therapeutics common stock directly.
TVTX submitted a Form 144 notice reporting proposed sales tied to 04/13/2026 restricted stock vesting and recent open-market dispositions by Eric M. Dube. The filing lists 64,000 shares associated with the restricted stock vesting and five reported sales totaling specific share counts and proceeds in early 2026.
Morgan Stanley Smith Barney LLC submitted a Rule 144 notice regarding proposed sales of Common stock tied to performance shares. The notice lists 6,785 performance shares dated 04/13/2026. It also records multiple recent dispositions by Elizabeth Reed, including 37,500 shares on 04/14/2026.
TVTX affiliate files a Form 144 to report a proposed sale of 1,014 common shares. The filing lists prior sales by Christopher Cline on specific dates, including a 7,239-share sale for $303,522.58 dated 04/14/2026. The notice identifies the securities as Performance Shares of common stock.
JULA INRIG reported transactions and an intended sale of performance-based common shares. The filing lists 1,018 Performance Shares dated 04/13/2026. It also discloses prior open‑market sales of Common stock: 7,215 shares for $302,516.29 on 04/14/2026, 6,956 shares for $223,429.38 on 02/03/2026, and 1,779 shares for $57,299.10 on 02/04/2026.
Elizabeth E. Reed reported proposed and recent sales of Common Stock under a Form 144 notice. The filing lists multiple transactions dated between 01/20/2026 and 04/14/2026, including single sales of 10,000 shares, 7,175 shares, 3,994 shares and a 37,500-share entry on 04/14/2026. The sales are tied to compensation and a performance restricted stock unit vesting event on 04/13/2026.
TVTX filing: Proposed sale notice under Form 144. The filing lists proposed sales of Common stock tied to Performance Restricted Stock Unit vesting on 04/13/2026, and recent dispositions in February 2026 by Jula Inrig: 1,779 shares on 02/04/2026 and 6,956 shares on 02/03/2026. The intermediary listed is Morgan Stanley Smith Barney.
TVTX reported a proposed sale of 7,215 shares of Common Stock on Form 144.
The filing lists 7,215 shares attributable to Performance Restricted Stock Unit vesting on 04/13/2026, described as compensation and routed through Morgan Stanley Smith Barney. The filing also shows 7,310 shares sold on 02/03/2026 in the prior three months.